Haleon (HLN) Receivables (2021 - 2026)

Haleon's (HLN) quarterly Receivables came in at $3.1 billion in Q2 2026, up 1.83% on a QoQ basis from $3.0 billion in Q4 2025.

Haleon (HLN) Receivables (2021 - 2026) Analysis & Trends

Haleon (HLN) has 6 years of Receivables data on file, last reported at $3.1 billion in Q2 2026.

Quarterly Receivables changed N/A year-over-year to $3.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.1 billion (changed N/A YoY) and the FY2025 annual result came in at $3.0 billion, down 0.51% from the prior year.
Receivables advanced to $3.1 billion in Q2 2026, from $3.0 billion in the prior quarter.
In the past five years, Receivables ranged from a high of $14.6 billion in Q2 2022 to a low of $2.6 billion in Q2 2023.
A 5-year average of $4.3 billion and a median of $2.9 billion in 2024 frame the typical range for Receivables.
Annual changes were most pronounced in 2023 — Receivables plunged 82.51% — and 2024, when it grew 5.36%.
Tracing HLN's Receivables over 5 years: stood at $2.8 billion in 2022, then increased by 0.41% to $2.9 billion in 2023, then gained by 4.27% to $3.0 billion in 2024, then gained by 1.19% to $3.0 billion in 2025, then climbed by 1.83% to $3.1 billion in 2026.
The last three Receivables figures came in at $3.1 billion (Q2 2026), $3.0 billion (Q4 2025), and $3.0 billion (Q4 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-	3.07 Bn
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn	3.49 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn	1.57 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn	5.84 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn	310.30 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn	3.67 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn	887.00 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	1.15 Bn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	1.08 Bn
10	Alkermes	8.02 Bn	7.37 Bn	397.90 Mn	456.48 Mn

Download Data